What Amgen Australia does

Amgen Australia Pty Ltd is a wholly-owned subsidiary of Amgen Inc. (NASDAQ: AMGN), established in 1991 and headquartered in Sydney at Level 11, 10 Carrington Street. The company markets a portfolio of 18 biologic and biosimilar medicines across oncology and hematology (BLINCYTO®, KYPROLIS®, LUMAKRAS®, Vectibix®, IMDELLTRA®), cardiovascular disease (Repatha®), osteoporosis and bone health (Prolia®, XGEVA®, CORORA®, EVENITY®), inflammation (AMGEVITA®, Otezla®, WEZLANA®), and rare diseases, alongside multiple biosimilars (KANJINTI®, MVASI®, GANVADO®) referencing originator biologics.

The underlying technology platform is rooted in recombinant DNA technology, genetic engineering, and protein-based therapeutics manufactured using living cells (mammalian cells and E. coli). Amgen's parent operates world-class biomanufacturing scale, including a Singapore facility spanning 120,000 square meters with bioreactors up to 20,000 liters. Discovery leverages AI, data science, generative biology, and machine learning for protein structure prediction and target identification, with the deCODE Genetics subsidiary providing multi-omics human genetics capabilities.

Amgen Australia's revenue model is prescription drug sales, with products distributed through pharmacy channels and priced via Australia's Pharmaceutical Benefits Scheme (PBS). The go-to-market is enterprise field sales engaging physicians, pharmacists, and nurses, supported by dedicated healthcare professional portals (amgenassist.com.au), medical information services, and adverse event reporting infrastructure. Australia participates in 36% of Amgen's global interventional clinical trials, embedding the subsidiary in the parent's R&D pipeline and providing early access to first-in-human studies and pipeline assets.

Name

Amgen Australia

Legal name

Amgen Australia Pty Ltd

Website

https://amgen.com.au

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Amgen Australia Pty Ltd is a Sydney-based subsidiary of Amgen Inc. that markets 18 biologic and biosimilar medicines across oncology, cardiovascular disease, osteoporosis, and inflammation, distributed through PBS pharmacy channels and supported by enterprise field sales targeting Australian healthcare professionals and hospitals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Biologic medicines
• Oncology therapeutics
• Biosimilar medicines
• Osteoporosis treatments
• Cardiovascular biologics

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Amgen Australia generates revenue through the sale of biologic medicines for serious illnesses including cancer, cardiovascular disease, osteoporosis, and inflammatory disorders. Products are distributed through pharmacy channels via prescription.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Amgen Australia develops, markets, and distributes a portfolio of 18 innovative biologic medicines and biosimilars for serious illnesses including cancer (BLINCYTO®, KYPROLIS®, LUMAKRAS®, Vectibix®, IMDELLTRA®), cardiovascular disease (Repatha®), osteoporosis and bone health (Prolia®, XGEVA®, CORORA®, EVENITY®, GANVADO®), inflammatory disorders (AMGEVITA®, Otezla®, WEZLANA®), and supportive care (Aranesp®, Nplate®). Products are manufactured using living-cell biotechnology, require prescription through Australia's Pharmaceutical Benefits Scheme (PBS), and are supported by healthcare professional portals, medical information services, and patient access programs.

Product overview

Amgen Australia operates as a biotechnology pharmaceutical company marketing a portfolio of innovative biologic medicines and biosimilars. The product portfolio includes 18 branded pharmaceutical products spanning oncology and haematology (BLINCYTO®, KYPROLIS®, LUMAKRAS®, Vectibix®), cardiovascular disease (Repatha®), osteoporosis and bone health (Prolia®, XGEVA®, CORORA®, EVENITY®), inflammation (AMGEVITA®, Otezla®, WEZLANA®), and rare diseases. Additionally, Amgen Australia markets multiple biosimilar products (KANJINTI®, MVASI®, GANVADO®, WEZLANA®) that reference originator biologics. The company also offers patient support programs, healthcare professional resources through AmgenAssist portal, and medical information services. The medicines are delivered via injection or infusion and are manufactured using living cell biotechnology processes.

Differentiator

Problem solved

Functional benefit

Products and services

• AMGEVITA® (adalimumab) A biosimilar referencing Humira containing adalimumab, a monoclonal antibody for the treatment of inflammatory disorders including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
• Aranesp® (darbepoetin) An erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease and chemotherapy-induced anemia.
• BLINCYTO® (blinatumomab) A bispecific T-cell engager (BiTE) immunotherapy used to treat acute lymphoblastic leukemia (ALL).
• CORORA® (denosumab) A RANK ligand inhibitor biosimilar for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
• EVENITY® (romosozumab) A sclerostin inhibitor used to treat osteoporosis by increasing bone formation and decreasing bone resorption.
• GANVADO® (denosumab) A biosimilar referencing Prolia® (denosumab) used for the treatment of osteoporosis and bone-related conditions.
• IMDELLTRA® (tarlatamab) A bispecific T-cell engager (BiTE) targeting DLL3 used for the treatment of advanced small cell lung cancer.
• KANJINTI® (trastuzumab) A biosimilar referencing Herceptin® (trastuzumab) used as a HER2-positive breast cancer treatment.
• KYPROLIS® (carfilzomib) A proteasome inhibitor used for the treatment of multiple myeloma.
• LUMAKRAS® (sotorasib) A KRAS G12C inhibitor for the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
• MVASI® (bevacizumab) A biosimilar referencing Avastin® (bevacizumab) used for various cancers including colorectal, lung, and ovarian cancer.
• Nplate® (romiplostim) A thrombopoietin receptor agonist used for the treatment of immune thrombocytopenia (ITP).
• Otezla® (apremilast) A PDE4 inhibitor for the treatment of psoriasis and psoriatic arthritis.
• Prolia® (denosumab) A RANK ligand inhibitor for osteoporosis, bone loss from hormone ablation therapy, and giant cell tumor of bone.
• Repatha® (evolocumab) A PCSK9 inhibitor used to lower LDL cholesterol in patients with cardiovascular disease or familial hypercholesterolemia.
• Vectibix® (panitumumab) An EGFR inhibitor for metastatic colorectal cancer with wild-type RAS.
• WEZLANA® (ustekinumab) A biosimilar referencing Stelara® (ustekinumab) used for psoriasis, psoriatic arthritis, and Crohn's disease.
• XGEVA® (denosumab) A RANK ligand inhibitor for prevention of skeletal-related events in patients with bone metastases from solid tumors and for giant cell tumor of bone.
• Medical Information Services Medical information and pharmacovigilance service for healthcare professionals and patients via dedicated phone line (1800 803 638), email ([email protected]), and the Amgen MedInfo portal (amgenmedinfo.com.au) for product enquiries, adverse event reporting, and product complaints.

Quantifiable outcome

• Millions of patients reached globally with Amgen medicines
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• The University of SydneycoreStrategic or Co-development PartnerSince 2016, The University of Sydney has partnered with Amgen to deliver the Amgen Biotech Experience (ABE) program to Australian high school students. The program provides teachers with professional development and education materials and loans research-grade equipment to schools at no cost.
• The University of MelbournecoreStrategic or Co-development PartnerSince joining the Amgen Scholars Program in 2019, the University of Melbourne has expanded access to research opportunities for undergraduates across Australia, New Zealand, and Oceania. Local research leaders mentor aspiring scientists during eight-week research placements in Melbourne's Biomedical Precinct each year.
• Harvard UniversitycoreStrategic or Co-development PartnerHarvard University developed LabXchange, a free online platform for science learning funded by the Amgen Foundation. The platform provides middle school, high school, and university level teachers and students with personalised instruction, virtual lab experiences, and networking opportunities.
• OzHarvestminorOthersOzHarvest is one of the organisations supported during Amgen Australia's Annual Week of Service, where staff volunteer to help address food waste and provide meals to those in need.
• IndigiGrowminorOthersIndigiGrow is an Aboriginal community organisation focused on cultural preservation and environmental regeneration. Supported during Amgen Australia's Annual Week of Service 2023.
• LandcareminorOthersLandcare is supported during Amgen Australia's Annual Week of Service, with staff volunteering to regenerate bushland and coastal areas.
• The Salvation ArmyminorOthersThe Salvation Army is supported during Amgen Australia's Annual Week of Service, with staff volunteering to prepare meals and provide support to those in need.
• Australian Packaging Covenant Organisation (APCO)coreStrategic or Co-development PartnerAmgen Australia has voluntarily signed the Australian Packaging Covenant, a framework for managing the environmental impacts of packaging. Amgen participates in APCO's annual awards program and has received multiple accolades including Outstanding Achievement in Sustainable Packaging Solutions.
• Wakka Wakka woman Brooke PrentiscoreOthersBrooke Prentis served as Amgen's RAP partner for the Reconciliation Action Plan launch, providing keynote speeches and guidance on the company's journey towards Reconciliation with Aboriginal and Torres Strait Islander peoples.
• Medicines AustraliacoreGTM or Marketing PartnerAmgen Australia is a member of Medicines Australia and complies with the Medicines Australia Code of Conduct. The company reports Transfers of Value to Healthcare Professionals and Healthcare Organisations in accordance with transparency requirements.
• Healthcare Consumer OrganisationscoreGTM or Marketing PartnerAmgen Australia provides financial and non-financial support to healthcare consumer organisations to provide information, support, and resources that improve prevention, diagnosis, treatment, and survival. Reports published in accordance with Medicines Australia Code of Conduct.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AbbVie Australia: AbbVie Australia is a primary competitor in immunology (Humira and Skyrizi) and oncology (Imbruvica), overlapping directly with Amgen's AMGEVITA, Otezla, and WEZLANA franchises. Same biologic manufacturing model and PBS-driven commercial approach.
• Novartis Australia: Novartis Australia sells innovative oncology, cardiovascular, and immunology biologics (e.g., Kymriah, Cosentyx, Entresto) through the same PBS and hospital channel structure. Highly comparable specialty pharma competitor with overlapping therapeutic areas and a similar biotech-grade discovery platform.
• Pfizer Australia: Pfizer Australia is a subsidiary of Pfizer Inc. and operates a similarly broad specialty/biologic pharmaceutical portfolio across oncology, inflammation, cardiovascular, and rare diseases, selling through PBS channels to Australian hospitals and prescribers. Directly comparable as a multinational pharma subsidiary duplicating the same commercial model in Australia.
• Roche Products Australia: Roche Australia markets a leading portfolio of oncology biologics (Herceptin, Avastin originator) and immunology products through Australian hospitals and the PBS. It is a direct competitor to Amgen's oncology and biosimilar franchises and shares the same biologic, hospital-channel, and enterprise-field-sales GTM model.
• AstraZeneca Australia: AstraZeneca Australia sells oncology (Tagrisso, Imfinzi), cardiovascular, and biologic products through Australian hospitals and PBS. Directly comparable in therapeutic breadth, biologic-heavy portfolio, and engagement with Australian HTA agencies.
• Sanofi Australia: Sanofi Australia markets specialty biologics in immunology (Dupixent), oncology, and rare diseases through the same hospital and PBS pathways. Comparable as a multinational pharma subsidiary with a biologics-led portfolio and similar enterprise sales motion.
• GSK Australia: GSK Australia operates a specialty and biologic pharmaceutical portfolio across oncology, immunology, and respiratory, distributed through Australian hospitals and the PBS. Comparable global pharma subsidiary with an overlapping field sales and medical affairs operating model.
• Johnson & Johnson (Janssen) Australia: Janssen Australia markets innovative oncology, immunology, and cardiovascular biologics through PBS and hospital channels. Comparable global pharma subsidiary with overlapping therapeutic areas and biologic manufacturing expertise.
• Merck Sharp & Dohme (MSD) Australia: MSD Australia markets Keytruda and other immuno-oncology and specialty biologics via PBS and private channels. Comparable as a global pharma subsidiary with a biologic-led, hospital-channel approach and strong clinical trial presence in Australian tertiary hospitals.
• Bristol-Myers Squibb Australia: BMS Australia markets Opdivo, Yervoy, and other immuno-oncology biologics through the same channels, with comparable enterprise sales, MSL, and patient access infrastructure. Directly competes with Amgen's oncology and biosimilar offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amgen
• Xx.com/amgen

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amgen Australia